

**Fax**

To
PCT Petition

Fax number
571 273 0459

From
Heidi M. Berven
Patent Attorney

URGENT

Fax number
+1 781 839 4121

Copies

Date
29 November 2005

Total pages
8

Subject
Petition to Revival
Application No.: 10/551325

Reference
Our Ref 100870-1P US

Please see attached documents

RECEIVED
29 NOV 2005
Legal Staff
International Division

This message, including any attachments, is confidential, intended only for the recipient, and may be a confidential attorney client communication or may otherwise be privileged and confidential and protected from disclosure. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, please be aware that any dissemination or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify us by replying to the message and deleting it from your computer. Thank you.

AstraZeneca
Global Intellectual Property
35 Gatehouse Drive
Waltham, MA 02451-1215
USA

Tel: +01 781 839-4000
Fax: +01 781 839-4121
www.astrazeneca-us.com

AstraZeneca R&D Boston
35 Gatehouse Drive
Waltham, Massachusetts 02451-1215
USA

BEST AVAILABLE COPY

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


7

Application Number	10/551325
Filing Date	September 23, 2005
First Named Inventor	Micahel Barry Gravstock
Art Unit	Not yet known
Examiner Name	Not yet known
Attorney Docket Number	100870-1P US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input checked="" type="checkbox"/> Petition Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Copies of Petition for Revival documents
<input type="checkbox"/> Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AstraZeneca		
Signature			
Printed name	Heidi M. Berven		
Date	Nov 29 2005	Reg. No.	48951

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Audrey Williams	Date	November 29, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY

COPY


Express Mail Label No.: ED 908733412 US
Attorney Docket No.: 100870-1P US

1 of 1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gravestock et al	Filed: Herewith
Application No.: Not yet assigned	Attorney Docket No.: 100870
PCT Application No.: PCT/GB2(04/001119	Examiner: Not yet assigned
Title: ANTIBACTERIAL 1,3-OXAZOLIDIN-2-ONE DERIVATIVES	

Mail Stop PCT
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450



**COMMUNICATION SUBMITTED WITH PTO/SB/64
PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT
DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 C.F.R. § 1.137(b)**

As provided in PTO/SB/64 attached herewith, Form PTO-1390 and the relevant fee for the captioned application was due for submission to the United States PTO on September 20, 2005. Form PTO-1390 and the relevant fee were unintentionally filed on September 21, 2005. Applicants hereby respectfully request revival of the application and reinstatement of Applicants' priority rights under 37 C.F.R. §1.137(b), in light of PCT Rule 82.2.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100870.

Respectfully submitted,

Name: Heidi Berven
Dated: Sept 23, 2005
Reg. No.: 48,951
Phone No.: 781-839-4336
Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760

BEST AVAILABLE COPY

Express Mail Label No.: ED 9087334121
 Attorney Docket No.: 100870-1P US

COPY

PTO/SB/64/PCT (12-04)
 Approved for use through 03/31/2007. OMB 0851-0021
 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT
 DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)**

Docket Number
 (Optional)
100870-1P-US

First Named Inventor: Michael Barry Gravestock

International (PCT) Application No.: PCT/GB2004/001119

U.S. Application No.:
 (if known)

Filed: March 20, 2003

Title: Antibacterial 1,3-Oxazolidin-2-one Derivatives

Attention: PCT Legal Staff
 Mail Stop PCT
 Commissioner for Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee which is required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

☐ Small entity - fee \$ _____ (37 CFR 1.17(m)). Applicant claims small entity status.
 See 37 CFR 1.27.

☒ Other than small entity - fee \$ See 1 (37 CFR 1.17(m))

2. Proper reply

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s)) in the form of
Form PTO-1390 (identify type of reply):

☒ has been filed previously on See 2 in Addendum

43 ☒ is enclosed herewith.

[Page 1 of 2]

This collection of information is required by 37 CFR 1.137(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9198 and select option 2.

BEST AVAILABLE COPY

COPY

PTO/SB/64/PCT (12-04)

Approved for use through 03/31/2007. OMB 0851-0021

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


3. Terminal disclaimer with disclaimer fee:

☒ Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.

☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.



Signature

Sept. 23

Date

Heidi M. Berven

Typed or Printed Name

48,951

Registration Number, if applicable

AstraZeneca R&D Boston

Address

781-839-4336

Telephone Number

35 Gatehouse Drive Waltham MA 02451

Address

Enclosures: ☒ Response☒ Fee Payment☐ Terminal Disclaimer☒ Other (please identify):

Copies of Form 1390 and associated information

COPY

Addendum

1. 1500. Please charge Deposit Account No. 50-3231, referencing Attorney Docket No. 100870-1P-US
2. Septemer 21, 2005. The fee and 1390 form were due on September 20, 2005. The fee and form were unintentionally filed on September 21, 2005.

BEST AVAILABLE COPY

COPY



ED 908733412 US

PRESS HARD. YOU ARE MAKING 3 COPIES.

ORIGIN (POSTAL SERVICE USE ONLY)		Postage	
PO ZIP Code	Day of Delivery <input type="checkbox"/> Next <input type="checkbox"/> 2nd <input type="checkbox"/> 2nd Dist. Day	\$	
Date Accepted	Scheduled Date of Delivery Month Day	\$	
Mo. Day Year	Scheduled Time of Delivery <input type="checkbox"/> Noon <input type="checkbox"/> 3 PM	COD Fee \$	Insurance Fee \$
Time Accepted <input type="checkbox"/> AM <input type="checkbox"/> PM	Military <input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Total Postage & Fees \$	
Flat Rate <input type="checkbox"/> or Weight lbs. ozs.	Int'l Alpha Country Code	Acceptance Emp. Initials	

FROM: (PLEASE PRINT) PHONE 781-839-4155
 Patents Administrator
 Global Intellectual Property
 AstraZeneca R&D Boston
 35 Calverhouse Drive
 Waltham MA 02451-1215 100870-1P US

FOR PICKUP OR TRACKING
 Visit www.usps.com
 Call 1-800-222-1811

Mailing Label
Label 11-B, March 2004

Post Office To Addressee

UNITED STATES POSTAL SERVICE®

DELIVERY (POSTAL USE ONLY)

Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Attempt	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		
Delivery Date	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Mo. Day		

CUSTOMER USE ONLY

PAYMENT BY ACCOUNT
Express Mail Corporate Acct. No.Federal Agency Acct. No. or
Postal Service Acct. No.

☐ WAIVER OF SIGNATURE (Domestic Mail Only)
 Additional merchandise insurance is void if
 customer requests waiver of signature.
 (with delivery) to be made without obtaining signature
 of addressee or addressee agent (if delivery employee
 judges that article can be left in secure location) and
 authorize that delivery employee's signature constitutes
 valid proof of delivery.

☐ NO DELIVERY
☐ Weekend ☐ Holiday ☐ Mailer Signature

TO: (PLEASE PRINT) PHONE 1

MAILSTOP PETITION
 COMMISSIONER FOR PATENTS
 P.O. BOX 1450
 ALEXANDRIA VA
 ZIP + 4 (U.S. ADDRESSES ONLY. DO NOT USE FOR FOREIGN POSTAL CODES)
 2 2 3 1 3 + 1 4 5 0

FOR INTERNATIONAL DESTINATIONS, WRITE COUNTRY NAME BELOW.

EXPRESS MAIL LABEL NO: ED 908733412 US

In re: US National Entry

Title: ANTIBACTERIAL 1,3-OXAZOLIDIN-2-ONE DERIVATIVES

Inventor (s): Gravestock et al

Date Filed: Herewith

Receipt is hereby acknowledged for the following in the United States Patent and Trademark Office:

1. Petition for Revival of an Application (3 sheets)
2. Communication submitted with PTO/SB/64 (1 sheet)
3. Attachments (7 documents)
4. Postcard

Attorney Docket No.: 100870-1P US Ref: HBE/aw

BEST AVAILABLE COPY

*** RX REPORT ***

INCOMPLETE RECEPTION

TX/RX NO	9601	
RECIPIENT ADDRESS	17818394121	
DESTINATION ID		
ST. TIME	11/29 13:30	
TIME USE	01'13	
PGS.	8	
RESULT	NG	##0106

BEST AVAILABLE COPY